logo-loader
viewWebjet Ltd

S&P/ASX 200 futures down as US markets down overnight

Overnight both the S&P 500 Index and the Nasdaq Composite closed down 4.41%.

Webjet Ltd - S&P/ASX 200 futures down as US markets down overnight
Concerns rise as the COVID-19 outbreak in the US may be worse than expected

S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) futures are down around 3% heading into the open today after the ASX 200 closed up 3.58% to 5,258.60 yesterday.

The daily increases for COVID-19 cases and deaths in the US continue to rise to new highs, which has the market concerned the pandemic is worse than expected.  

The S&P 500 Index (INDEXSP:.INX) closed at 2,470.50, −114.09 or down 4.41% and the Nasdaq Composite (INDEXNASDAQ: .IXIC) closed at 7,360.58, −339.52 or down 4.41%.

The Australian share market has had a solid week but will likely give some of this week’s gains back today.

Webjet Limited (ASX:WEB) could be in for a bumpy ride if it decides to recommence trading today after shares have been suspending recently to raise capital at $1.70 vs last traded price of $3.76.

 

 

Gold back above US$1,600, oil also rising

Gold has increased 0.4% overnight to be trading at US$1,603 per ounce while Crude Oil WTI was also 3.5% higher overnight to US$21.19 per barrel.

Oil was at US$20.00 per barrel during the night but sharply bounced off that level which is acting as support to the price short term.

The AUD is down slightly overnight and is buying 60.7 US cents after reaching 62 cents in the days prior but not being able to break through that level.

Quick facts: Webjet Ltd

Price: 4.44 AUD

ASX:WEB
Market: ASX
Market Cap: $1.51 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Kazia Therapeutics working on moving its flagship Paxalisib drug into...

  Kazia Therapeutics Ltd's (ASX:KZA) James Garner speaks to Proactive's Andrew Scott after releasing a poster presentation of interim data from the ongoing phase II study of Paxalisib in glioblastoma at the prestigious American Society of Clinical Oncology (ASCO) annual meeting. Analysis...

2 hours, 49 minutes ago

2 min read